Consortium
18 partners

Total budget
7,5 M€

Duration
42 months

Funded by the
European Union

www.enviromed.eu

This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No.101057844

enviromed

enviromed

ENVIROMED engages leading industrial partners in a participatory development of new methods, applies novel sensing methods and delivers a clear strategy roadmap for exploitable outcomes as well as engages citizens, health care providers and health systems for a Green Pharmaceuticals dialogue. 18 partners from 11 EU countries gathered for 42 months to cooperate in providing means and methodology, which shall contribute to the Green Pharmaceuticals concept in the EU and shall focus on scientific impacts aligned with the **ENVIROMED** vision for the deployment of optimised, green production methods and better understanding of pharmaceuticals' environmental impact.

A NEXT GENERATION TOOLBOX

The project aims to develop a set of technologies that enable greener and overall, more efficient pharmaceuticals production:

- Green-by-design in-silico drug development
- Novel sensing to allow reduction of rinsing chemicals and cycles
- A Robust Continuous Biomanufacturing line (CBM), which makes use of AI-enabled process optimisation and prediction

ENVIROMED addresses two aspects of the environmental impact of pharmaceuticals:

- impact of the processes in manufacturing the compound
- impact of the compound itself, during its lifecycle.

Strategic objectives

- Better understand the concentration levels and ecotoxicity of pharmaceuticals
- Develop low environmental footprint manufacturing processes while increasing resilience
- Reduce the overall environmental footprint of pharmaceuticals, throughout their lifecycle

The project narrows the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives in the environment, as it enables the better understanding of the environmental impact of such compounds throughout their lifecycle. It aims to offer (via extensive monitoring campaigns and scientific studies) information regarding occurrence of pharmaceuticals in the environment, their persistence, environmental fate, and toxicity (via in-vitro and in-vivo models) as well as application of in-silico methods to provide information about the basic risk management and fate prediction in the environment.

Linkedin Youtube Facebook

ENVIROMED and four other Horizon Europe Research projects, forms a new Green Pharmaceuticals Cluster

The aim of the Cluster is to capitalize on synergistic development. The aim of this cluster of R&D projects is to increase the sustainability of pharmaceutical products and exploit research synergies to boost the impact of innovations